Literature DB >> 29407554

Topical formulations of delta-aminolevulinic acid for the treatment of actinic keratosis: Characterization and efficacy evaluation.

Laura Risaliti1, Vieri Piazzini1, Maria Giuseppina Di Marzo2, Luigi Brunetti3, Roberto Cecchi3, Patrizia Lencioni4, Anna Rita Bilia1, Maria Camilla Bergonzi5.   

Abstract

Actinic keratosis (AK) is a pre-cancerous disease, with worldwide increasing incidence, which consists in squamous cutaneous lesion caused by excessive exposure to ultraviolet radiation. An established treatment option is photodynamic therapy (PDT), based on light, oxygen and a photosensitizer. The most widely used is 5-aminolevulinic acid (ALA) which however, being a hydrophilic molecule, has difficultly penetrating the skin to achieve the desired therapeutic effect. To solve this limit, the present study provides for the development of three galenic gel formulations (Natrosol, Sepigel and Carbopol) containing 10% w/w of ALA for the treatment of AK with PDT and their comparison with a lipophilic cream used in the Hospital. The aim of this study is to offer an appealing topical treatment that improves patients' observance and compliance. Formulations were characterized in terms of chemical, physical and microbiological stability, viscosity and pH. An HPLC-DAD analytical method was also developed and validated. Sepigel gel resulted the best gel formulation in terms of technological characteristics and stability. A comparative study between this gel and the lipophilic cream was assessed, by evaluating the therapeutic efficacy and the compliance of the patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-aminolevulinic acid; Actinic keratosis; Efficacy evaluation; Stability study; Topic delivery

Mesh:

Substances:

Year:  2018        PMID: 29407554     DOI: 10.1016/j.ejps.2018.01.045

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  1 in total

1.  Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.

Authors:  Diana Berenguer; Lilian Sosa; Magdalena Alcover; Marcella Sessa; Lyda Halbaut; Carme Guillén; Roser Fisa; Ana Cristina Calpena-Campmany; Cristina Riera
Journal:  Pharmaceutics       Date:  2019-11-15       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.